81.8 Billion Won Rights Offering Completed, Issue Price 4,860 Won, Top Shareholder Stake Diluted to 56.62%


  • Completed rights offering with subsequent general public offering, raising 81.8 billion won (16,830,200 shares at issue price of 4,860 won)
  • All proceeds (81.8 billion won) to be used for operational expenses
  • Top shareholder Yuhan Corporation participated in the offering, increasing its share count (from 48,891,724 to 51,633,393 shares), but ownership diluted from 65.75% to 56.62%
  • Existing shareholders subscribed 89% of allotments, oversubscription allocation ratio of 72.1%; some shares lapsed (1,845,595), and fractional shares of 6,781 acquired by lead manager
  • New shares listing date: June 8, 2026
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: Securities Issuance Performance Report
  • Company: ImmuneOncia Therapeutics (424870)
  • Submission: ImmuneOncia Therapeutics, Inc.
  • Receipt: 05-21-2026